Cancer Commons is a non-profit network of patients, physicians, and scientists united by a shared goal—to optimize each patient’s outcome and maximize collective learning to benefit the next patient.

Our Services

Since our founding in 2011, we have delivered personalized, evidence-based guidance at no charge to more than 10,000 patients and caregivers, supported entirely by philanthropy.

Get Help

Cancer Commons is staffed by accomplished researchers with PhDs in the molecular biology and pharmacology of cancer and in Artificial Intelligence. They have joined the Commons to apply their knowledge and expertise to help patients research their options in real time using the latest tools of precision oncology.

Meet the Team
  • RECURRENT CANCER: Unique Treatment Guidance After Cancer Returns. Webinar recording now available.
    Recurrent Cancer: Unique Treatment Guidance After Cancer Returns—Webinar Recording Now Available

    June 27, 2023

    Cancer Commons’ most recent webinar, Recurrent Cancer: Unique Treatment Guidance After Cancer Returns, was held virtually June 14, 2023. During the presentation, Dennis Watson, VP of Business Development of Travera, provided viewers with information and updates on a cancer therapy guidance test designed to predict which cancer drugs are most likely to be effective for individual cancer patients. Travera’s unique technology now applies to many cancers… Read more »

  • Photo of Cancer Commons Scientist Adrienne Nugent, PhD with Cancer Commons logo
    Get to Know Cancer Commons Scientist Adrienne Nugent, PhD

    April 5, 2023

    Adrienne Nugent, PhD, has always loved a good puzzle. Growing up, she enjoyed solving math problems, and in college at Duke University, chemistry inspired her puzzle-solving passion. She continued to apply this skill as she earned her PhD in genetics and genomics, also at Duke. Since then, she has found a through-line between her love for puzzles and her love for working directly with… Read more »

  • Cancer Commons logo next to the word WEBINAR, over the title of the webinar: A New Technology for Rapid Therapy Guidance
    A New Technology for Rapid Therapy Guidance: Webinar Recording Now Available

    December 16, 2022

    Cancer Commons’ most recent webinar, A New Technology for Rapid Therapy Guidance, was held virtually December 14, 2022. This presentation and Q&A session introduced viewers to a new cancer therapy guidance test that is designed to predict which cancer drugs are most likely to be effective for individual cancer patients. Cancer Commons CEO Rebecca Driscoll introduced Clifford Reid, PhD (Founder and CEO) and Dennis Watson (VP… Read more »

More News...

  • When questions arose about my husband’s case, one of the researchers (Matthew) took time to personally call me and discuss his case.

    Tracy
    Wife of glioblastoma patient

  • Cancer Commons is truly unique at rapidly matching patients with advanced cancer with the best precision therapy or clinical trial.

    E. David Crawford, MD
    Cancer Commons Advisor

  • Whenever we needed them they were there. Whenever we needed new information or help finding a new treatment they were there immediately. They were such a pleasure to deal with that they were like a family member helping you out, and believe me I/we needed them. 

    Dr. Mel Burchman
    Spouse of a pancreatic cancer patient

  • Words cannot describe enough the help, guidance, services, and advice I received from Cancer Commons—whether from online resources, the constant support provided by the dedicated scientist Dr. Matt Warner, or the selfless recommendations from a tumour board, so that at least I know what other experts are thinking and where treatment could be headed potentially, and plan course of action accordingly.

    Viji
    Wife of a glioblastoma patient

  • Sincere thanks to Cancer Commons and their Virtual Tumor Board for their comprehensive analysis and recommendations regarding treatments for my pancreatic cancer. I feel fortunate to have the benefit of the expertise offered by their board of scientists, researchers, physicians, and experts in this field.

    Roy Saenz